Abbott and Withings partner to offer OTC CGM Lingo on Withings’ connected health platform –
Sensors will be available for $89 per month through Withings; glucose data will directly integrate with the Withings platform
France-based Withings announced today that it has partnered with Abbott to sell its OTC CGM Lingo and to integrate CGM data with its broader healthcare platform. Withings users can monitor over 90 biomarkers with the company’s smart devices, including vascular age, fat versus muscle content, body water content, and resting heart rate, per the company. Lingo sensors are now available for purchase on the Withings US website at $89 for two sensors, the same price offered by Abbott on HelloLingo.com. Glucose data is currently available by pairing the Withings Health Mate app with Apple Health for iOS and Health Connect for Android. Early this quarter, glucose data is expected to be directly integrated with the Withings app through a direct application programming interface with the Lingo app. This expansion of availability with a focus on a broad range of users further promotes a popular, lifestyle-focused use of CGM.
Withings integration follows Lingo availability through Walgreens, Walmart, Amazon, and HelloLingo.com
Lingo initially launched in September 2024, available directly from Abbott through HelloLingo.com. In February 2025, the device became available on Amazon, followed by Walmart in October 2025, marking Lingo’s first large-scale brick-and-mortar presence. Last month, Abbott partnered with Walgreens, extending this approach. Lingo is now available in two physical national pharmacy chains, strengthening its visibility among consumers. We look forward to further updates on the success of brick-and-mortar versus online sales. While Abbott has yet to disclose Lingo app downloads or other utilization metrics, Dexcom’s Stelo had over 400,000 downloads per the last reported figures in 2Q25.
OTC CGMs Lingo and Stelo continue to be promoted as lifestyle devices
Withings said that the integration of glucose data with the company’s ecosystem is specifically designed to encourage consumers to take control of their health and referenced the over 98 million Americans that currently have prediabetes. With the integration of glucose data, Withings hopes to reduce the risk of insulin resistance, developing T2D, and heart disease.
Abbott has previously suggested that 95% of Lingo users report adopting new habits based on glucose insights and said that 80% of Americans fail to recognize glucose as a key health indicator. Abbott has also targeted the chronic disease prevention and pre-diabetes markets while focusing on the need for glucose awareness. By predominantly showing users how food, exercise, and stress impact glucose in real time and suggesting small lifestyle changes for optimization, Abbott aims to distinguish Lingo from its FreeStyle Libre platform to develop a new wellness-focused user base.
Suite of biometrics adding to options for holistic approach
In May 2025, Dexcom and Oura launched a partnership that incorporated sleep data from the Oura ring with glucose data from Dexcom’s OTC CGM, Stelo. In its lineup of products, Withings has a sleep mat that analyzes users’ sleep quality and trends, along with duration. While this has historically been used for analysis of cardiovascular health and risk of obstructive sleep apnea, we are curious if this might be incorporated into glucose analysis, similar to the offering from Dexcom and Oura.
Close Concerns’ Questions
- Will the Withings platform support the use of Lingo sensors not purchased through Withings?
- How will interoperability for OTC CGMs continue to be explored in the future?
- How will health insights offered by Withings combine glucose data with other health metrics such as sleep quality, blood pressure, resting heart rate, and body composition?
- Will Withings continue to expand the types of recommendations based on glucose values over time?
-- by Nour Khachemoune, Monica Oxenreiter, and Kelly Close